162 related articles for article (PubMed ID: 10160102)
21. [Pharmacoeconomic aspects of the treatment of essential hypertension].
Martynov AI; Giliarevskiĭ SR; Ostroumova OD; Nesterova MV; Mamaev VI
Ter Arkh; 2001; 73(9):82-8. PubMed ID: 11642090
[No Abstract] [Full Text] [Related]
22. Mild-to-moderate uncomplicated hypertension: further analysis of a cost-effectiveness study of five drugs.
Richter A; Gondek K; Ostrowski C; Dombeck M; Lamb S
Manag Care Interface; 2001 Jul; 14(7):61-9. PubMed ID: 11481819
[TBL] [Abstract][Full Text] [Related]
23. Considerations in the treatment of mild-to-moderate hypertension.
Giaquinta D
Manag Care Interface; 2001 Mar; 14(3):80-1. PubMed ID: 11301960
[No Abstract] [Full Text] [Related]
24. Identification of factors driving differences in cost effectiveness of first-line pharmacological therapy for uncomplicated hypertension.
Klarenbach SW; McAlister FA; Johansen H; Tu K; Hazel M; Walker R; Zarnke KB; Campbell NR;
Can J Cardiol; 2010 May; 26(5):e158-63. PubMed ID: 20485695
[TBL] [Abstract][Full Text] [Related]
25. Pharmacoeconomic considerations in the management of hypertension.
Pardell H; Tresserras R; Armario P; Hernández del Rey R
Drugs; 2000; 59 Suppl 2():13-20; discussion 39-40. PubMed ID: 10678593
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the total cost of treating elderly hypertensive patients with ACE inhibitors: a comparison of older and newer agents.
Small RE; Freeman-Arnold SB; Goode JV; Pyles MA
Pharmacotherapy; 1997; 17(5):1011-6. PubMed ID: 9324190
[TBL] [Abstract][Full Text] [Related]
27. [Health care too costly? Saving more than 10 million euros in 2 months!].
Rappert B
MMW Fortschr Med; 2003 Nov; 145(47):65. PubMed ID: 14725043
[No Abstract] [Full Text] [Related]
28. Hypertension control: improved, but not enough!
Alderman MH
Am J Hypertens; 2007 Apr; 20(4):347. PubMed ID: 17386338
[No Abstract] [Full Text] [Related]
29. [Antihypertensive treatment. Benefits and costs].
Jensen HA; Svendsen TL
Ugeskr Laeger; 1993 Jan; 155(2):118-20. PubMed ID: 8421861
[No Abstract] [Full Text] [Related]
30. The direct costs to the NHS of discontinuing and switching prescriptions for hypertension.
Hughes D; McGuire A
J Hum Hypertens; 1998 Aug; 12(8):533-7. PubMed ID: 9759987
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness issues in hypertension control.
Schueler K
Can J Public Health; 1994; 85 Suppl 2():S54-6. PubMed ID: 7804952
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin receptor blockers: impact on costs of care.
Am J Manag Care; 2005 Nov; 11(13 Suppl):S400-3. PubMed ID: 16300456
[TBL] [Abstract][Full Text] [Related]
33. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic.
Caro JJ; Lee K
Curr Hypertens Rep; 2002 Dec; 4(6):418. PubMed ID: 12419167
[No Abstract] [Full Text] [Related]
34. The cost effectiveness of hypertension treatment in Sweden.
Johannesson M
Pharmacoeconomics; 1995 Mar; 7(3):242-50. PubMed ID: 10155314
[TBL] [Abstract][Full Text] [Related]
35. [Fully possible to reduce the costs of hypertension treatment].
Wettermark B; Angman A; Hjemdahl P
Lakartidningen; 2009 Jun 3-9; 106(23):1558-62. PubMed ID: 19583013
[No Abstract] [Full Text] [Related]
36. Improving cost-effectiveness of hypertension management at a community health centre.
Edwards PR; Lunt DW; Fehrsen GS; Lombard CJ; Steyn K
S Afr Med J; 1998 May; 88(5):549-54. PubMed ID: 9638122
[TBL] [Abstract][Full Text] [Related]
37. Assessing the economic value of antihypertensive medications.
Roth MS; Davenport RC; Simpson W
Am J Manag Care; 1998 Sep; 4(9):1267-75. PubMed ID: 10185977
[TBL] [Abstract][Full Text] [Related]
38. [The basic treatment of arterial hypertension (II). Pharmacological treatment].
Pascual J; Orte L; Ortuño J
Med Clin (Barc); 1994 Nov; 103(18):699-707. PubMed ID: 7808078
[No Abstract] [Full Text] [Related]
39. Costs of implementing recommendations on hypertension management given in recent guidelines.
Zanchetti A
J Hypertens; 2003 Dec; 21(12):2207-9. PubMed ID: 14654733
[No Abstract] [Full Text] [Related]
40. [Treatment of hypertension. Between progress and cost control].
MMW Fortschr Med; 1999 Oct; 141(42):46. PubMed ID: 10912105
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
